Roche Holding expects sales and core earnings to keep growing this year after beating analysts' expectations for 2024. The Swiss pharmaceutical giant is forecasting sales growth in the ...

She writes a regular blog on her experiences for the Warrington Guardian. Where is the time going? We’re already half way through January and Christmas seems a million miles away, but I hope everyone ...

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...

The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for ...

And, in fact, this study showed that the additional palbociclib to this kind of treatment was able to significantly prolong PFS from the start of the maintenance treatment with a benefit in terms of ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.COWbVb-l.js ...

Moreover, the cells demonstrated improved growth and, compared to similarly treated controls, produced significantly higher yields of protein-based drugs such as Herceptin and Rituximab ...

“I have two more Herceptin infusions and then I will get ... she’s been working on her physical health after receiving treatment. “And I’m working out with @bodyfitbyamy to keep my body ...